Clinical value of molecular subtyping multiple myeloma using gene expression profiling

• Published in: Leukemia Vol. 30; no. 2; pp. 423 - 430
• Main Authors: Weinhold, N, Heuck, C J, Rosenthal, A, Thanendrarajan, S, Stein, C K, Van Rhee, F, Zangari, M, Hoering, A, Tian, E, Davies, F E, Barlogie, B, Morgan, G J
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2016; Nature Publishing Group
• Subjects: 38; 38/61; 631/67/69; Bortezomib; Cancer Research; Care and treatment; Classification; Critical Care Medicine; Development and progression; Disease-Free Survival; Gene expression; Gene Expression Profiling; Genetic aspects; Genotype; Genotypes; Health aspects; Health risk assessment; Hematology; Humans; Identification and classification; Intensive; Internal Medicine; Medicine; Medicine & Public Health; Methods; Multiple myeloma; Multiple Myeloma - classification; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - mortality; Oncology; original-article; Recurrence; Remission; Response rates; Risk; Risk groups; Subgroups; Survival; Thalidomide; United States
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/leu.2015.309

Using a data set of 1217 patients with multiple myeloma enrolled in Total Therapies, we have examined the impact of novel therapies on molecular and risk subgroups and the clinical value of molecular classification. Bortezomib significantly improved the progression-free survival (PFS) and overall survival (OS) of the MMSET (MS) subgroup. Thalidomide and bortezomib positively impacted the PFS of low-risk (LoR) cases defined by the GEP70 signature, whereas high-risk (HiR) cases showed no significant changes in outcome. We show that molecular classification is important if response rates are to be used to predict outcomes. The t(11;14)-containing CD-1 and CD-2 subgroups showed clear differences in time to response and cumulative response rates but similar PFS and OS. Furthermore, complete remission was not significantly associated with the outcome of the MAF/MAFB (MF) subgroup or HiR cases. HiR cases were enriched in the MF, MS and proliferation subgroups, but the poor outcome of these groups was not linked to subgroup-specific characteristics such as MAF overexpression per se . It is especially important to define risk status if HiR cases are to be managed appropriately because of their aggressive clinical course, high rates of early relapse and the need to maintain therapeutic pressure on the clone.